P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Update

P3 Health Partners Inc. (NASDAQ:PIII) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 68,522 shares, a decline of 50.4% from the May 31st total of 138,133 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily volume of 103,356 shares, the days-to-cover ratio is presently 0.7 days.

P3 Health Partners Price Performance

Shares of NASDAQ:PIII traded down $0.62 on Tuesday, reaching $11.32. The company’s stock had a trading volume of 14,350 shares, compared to its average volume of 692,589. P3 Health Partners has a 52-week low of $1.52 and a 52-week high of $16.89. The stock has a market capitalization of $81.96 million, a P/E ratio of -0.29 and a beta of 1.57. The stock’s 50-day moving average is $8.81 and its two-hundred day moving average is $4.98.

P3 Health Partners (NASDAQ:PIII) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.85) by $5.17. P3 Health Partners had a negative return on equity of 302.33% and a negative net margin of 8.57%.The firm had revenue of $386.39 million for the quarter, compared to analyst estimates of $391.45 million.

Institutional Investors Weigh In On P3 Health Partners

An institutional investor recently bought a new stake in P3 Health Partners stock. Lido Advisors LLC acquired a new stake in P3 Health Partners Inc. (NASDAQ:PIII) during the first quarter, according to its most recent filing with the SEC. The firm acquired 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned about 0.15% of P3 Health Partners at the end of the most recent reporting period. Institutional investors and hedge funds own 7.75% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Lake Street Capital restated a “buy” rating and set a $14.00 price objective (up from $4.00) on shares of P3 Health Partners in a research report on Friday, May 15th. Weiss Ratings upgraded shares of P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. TD Cowen reaffirmed a “hold” rating and set a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a report on Friday, May 22nd. Finally, UBS Group set a $14.00 target price on P3 Health Partners in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $14.00.

P3 Health Partners Company Profile

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.